DAVID P. EVITTS
***** ****** ***** **** *****: 949-***-****
Laguna Hills, California 92656-2804 eMail: ada3rp@r.postjobfree.com
FORMULATION DEVELOPMENT SCIENTIST
Experienced formulation development scientist desiring an opportunity to utilize a strong background in pharmaceutical pre-formulation and formulation development, employing data interpretation and problem solving skills.
SUMMARY OF QUALIFICATIONS
Twenty plus years of experience in the pharmaceutical industry concentrating in pre-formulation and formulation development. Areas of expertise are:
Dosage Forms
Technologies
Other
• parenteral
• formulation development
• product transfer
• ophthalmic
• pre-formulation development
• in vitro / in vivo modeling
• topical (semi-solid)
• statistical experimental design
• organic chemistry
• emulsification
• physical / chemical evaluation
• particle sizing (comprehensive)
• solid-state characterization
• drug delivery
• patent application writing
• nanotechnology
• quality by design (QbD)
• analytical methodologies
• statistical analysis
PROFESSIONAL EXPERIENCE
DPE CONSULTING, Laguna Hills, CA 4/2012 to Present
Consultant, Drug Delivery Technologies
Consulting on parenteral, ophthalmic and topical drug formulations.
AVRIO BIOPHARMACEUTICALS, LLC. Irvine, CA 1/2008 to 3/2012
Supervisor, Drug Delivery Technologies
Developed stable parenteral emulsions for drug delivery systems.
Developed cream and gel products for topical drug delivery through the skin.
Developed analytical methods to determine the quality of formulations.
Reverse engineered ophthalmic formulations for ANDA clients.
Conducted pre-formulation/formulation development for pre-clinical testing.
Participated in technical problem solving and technology transfers.
Interacted productively between departments within the company and with clients.
SYNTHETIC BLOOD INTERNATIONAL, INC., Costa Mesa, CA 1/2000 to 12/2007
Research Scientist
Advanced fluorocarbon based emulsions for the next generation of blood substitutes.
Developed products to assist in liquid breathing technology.
Developed analytical methods to determine the quality of emulsion formulations.
Conducted pre-formulation/formulation development with in vivo testing to support pharmacology and toxicology screening.
Participated in technical problem solving and patent writing.
Interacted productively between QC/QA, Regulatory and Clinical Research consultants.
ALLIANCE PHARMACEUTICAL CORP., San Diego, CA 1/1991 to 12/1999
Associate Scientist
Invented ultrasound contrast agents and experienced the drug development process from conception through NDA approval.
Developed analytical methods to determine the quality of ultrasound contrast formulations.
Conducted pre-formulation/formulation development with in vivo testing to support pharmacology and toxicology screening.
Participated in technical problem solving and patent writing.
Interacted productively between Process Development, QC/QA, Regulatory, Clinical Research, and Manufacturing Departments.
IOLAB PHARMACEUTICALS, INC., Claremont, CA 6/1984 to 12/1990
DIV. OF JOHNSON & JOHNSON
Research Associate
Developed novel drug delivery systems and sub-micron emulsions for ophthalmic use.
Formulated new active drug entities for ophthalmic solutions and suspensions.
Designed formulations with the use of in vivo and in vitro models.
Developed analytical methods to determine the qualitative and quantitative results of formulations created.
EDUCATION
B.S., California State Polytechnic University, Pomona, CA
Major: Chemistry (Biochemistry Option)
Minor: Computer Science
CONTINUING EDUCATION
University of California at San Diego, CA
Biomedical Sciences
PROFESSIONAL DEVELOPMENT
American Association of Pharmaceutical Scientists
UNITED STATES PATENTS
US5720938 – Systems for the formation of microbubbles
US5695741 – Stable microbubble precursors
US5639443 – Stabilized microbubble compositions
US5626833 – Ultrasound imaging method using microbubbles
US5605673 – Stabilized microbubble compositions for ultrasound
US6258339 – Osmotically stabilized microbubble preparations
US6280704 – Ultrasound imaging system utilizing a long-persistence contrast agent
US6287539 – Methods of imaging using osmotically stabilized microbubble preparations
US6372195 – Mixed gas bubble compositions
US6706253 – Osmotically stabilized microbubble preparations
US6939531 – Ultrasonic imaging system utilizing a long-persistence contrast agent
US6953569 – Mixed gas microbubble compositions
US7005120 – Osmotically stabilized microbubble preparations
EUROPEAN PATENTS
EP1550464 – Stabilized microbubble compositions for ultrasound
EP0711179 – Stabilized microbubble compositions for ultrasound
EP0480690 – Aqueous ophthalmic microemulsions of tepoxalin
SELECTED ABSTRACTS
Karyn A. Pinson, Heather D. Coffin, Lisa H. Mai, Bao Q. Truong, Reyn K. Ono, David P. Evitts, Rudy Flach and Charles E. Petersen, “Improvements in Anion Exchange HPLC Purity Analysis of Double-Stranded Nucleic Acid Drugs”, TIDES Conference, Las Vegas, NV, 2009 May.
D. Evitts and R. Kiral, “Development and Properties of Oxycyte: a New Perfluorocarbon Blood Substitute”, American Association of Pharmaceutical Scientists, Annual Session; Poster #W4173, Toronto, Canada, November, 2002
Mattrey RF, Wrigley R, Steinbach GC, Schutt EG, Evitts DP, “Gas Emulsions as Ultrasound Contrast Agents. Preliminary Results in Rabbits and Dogs”, Investigative Radiology, 1994 June; Volume 29, Supplement 2, S139 - S141
D. Evitts, D. Musson, A. Bidgood and O. Olejnik, “Development and Evaluation of an Ocular Microemulsion of RMI-1068, a Poorly Water-Soluble Non-Steroidal Anti-Inflammatory Agent”, American Association of Pharmaceutical Scientists, Annual Session; Poster #PD 7146, Las Vegas, Nevada, November, 1990
D. Musson, A. Bidgood, D. Evitts and O. Olejnik, “Enhanced Stability of Thymoxamine in Aqueous Solutions by Complexation with Dimethyl-ß-Cyclodextrin”, American Association of Pharmaceutical Scientists, Annual Session; Poster #PD 992, Atlanta, Georgia, October, 1989